NBIX Maintained by BMO Capital -- Price Target Lowered to $150

gurufocus.com · 2026-10-12

Neurocrine Biosciences (NBIX) Analyst Rating Update On October 12, 2026, BMO Capital's analyst Evan Seigerman announced that they have maintained the rating

TickrTrends take: BMO Capital's price target reduction to $150 for NBIX occurs within a Healthcare sector context where TickrTrends currently derives an Undervalued verdict for the stock. A valuation-focused reader should monitor whether this target adjustment reflects changing fundamental assessments or market conditions that might affect the gap between current trading levels and the newly established target price. The relationship between analyst price targets and TickrTrends' valuation assessment may indicate differing perspectives on where intrinsic value lies.

Read the full story at gurufocus.com →